Racial disparities persist in prostate cancer (CaP) treatment and survival, but disparities in androgen deprivation therapy (ADT) and the degree to which it affects racial differences in survival remains to be fully assessed.
Methods
Using the Surveillance, Epidemiology and End Results-Medicare linked data, we examined a large cohort of men (N = 64,475) diagnosed with locoregional CaP during 1992 to 1999 and followed through 2003. The effects of ADT and race on survival were analyzed using a Cox proportional hazards model.
Results
The receipt of ADT was significantly lower in African Americans (24%) relative to Caucasians (27%), Asians (34%), and Hispanics (28.7%) (P < .05). Compared with Caucasian race, African American race was associated with a statistically significant increased mortality (HR = 1.26, 95% CI = 1.21-1.32), which remained significant after adjusting for ADT but was substantially decreased after controlling for primary therapies such as radical prostatectomy, radiation, and watchful waiting (HR = 1.06, 95% CI = 1.01-1.10) and was no longer statistically significant after controlling for comorbidities (HR = 0.98, 95% CI = 0.94-1.03).
Conclusions
There were marked racial variations in the receipt of ADT, primary therapies (namely surgery and surgery combined with radiation), and comorbidities. However, racial disparities in survival were not affected by racial variations in ADT but were explained by racial variations in primary therapies and by racial differences in comorbidities.
References
1.
MillerB.A., KolonelL.N., BernsteinL.. Racial/Ethnic Patterns of Cancer in the United States 1988-1992. NIH Pub. No. 96-4104. Bethesda, MD: National Cancer Institute; 1996. http://seer.cancer.gov/publications/ethnicity/index.html. Accessed January 30, 2009.
2.
RiesL.A.G., EisnerM.P., KosaryC.L.. SEER Cancer Statistics Review, 1973-1999.Bethesda, MD: National Cancer Institute; 2002. http://seer.cancer.gov/csr/1973_1999/. Accessed December 9, 2008.
3.
JemalA., MurrayT., WardE.. Cancer statistics, 2005.CA Cancer J Clin.2005; 55(1): 10–30.
4.
ChuK.C., TaroneR.E., FreemanH.P.. Trends in prostate cancer mortality among black men in the United States.Cancer.2003; 97(6): 1507–1516.
5.
StanfordJ.L., StephensonR.A., CoyleL.M.. Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute. NIH Pub. No. 99-4543. Bethesda, MD, 1999.
6.
CleggL.X., LiF.P., HankeyB.F.. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study.Arch Intern Med.2002; 162(17): 1985–1993.
7.
HoffmanR.M., GillilandF.D., EleyJ.W.. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.J Natl Cancer Inst.2001; 93(5): 388–395.
8.
HarlanL., BrawleyO., PommerenkeF.. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate.J Clin Oncol.1995; 13(1): 93–100.
9.
MortonR.A.Jr. Racial differences in adenocarcinoma of the prostate in North American men.Urology.1994; 44(5): 637–645.
WingoP.A., BoldenS., TongT.. Cancer statistics for African Americans, 1996.CA Cancer J Clin.1996; 46(2): 113–125. Erratum in: CA Cancer J Clin. 1996; 46(3): 164.
12.
DayalH.H., ChiuC.. Factors associated with racial differences in survival for prostatic carcinoma.J Chronic Dis.1982; 35(7): 553–560.
13.
BennettC.L., PriceD.K., KimS.. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status.J Clin Oncol.2002; 20(17): 3599–3604.
ZeliadtS.B., PotoskyA.L., EtzioniR.. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.Urology.2004; 64(6): 1171–1176.
16.
YanY., CarvalhalG.F., CatalonaW.J.. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening.Cancer.2000; 88(5): 1122–1130.
17.
VijayakumarS., WeichselbaumR., VaidaF.. Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status.Cancer J Sci Am.1996; 2(4): 225–233.
18.
Demark-WahnefriedW., SchildkrautJ.M., IselinC.E.. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina.Cancer.1998; 83(2): 320–330.
19.
DemersR.Y., TiwariA., WeiJ.. Trends in the utilization of andro-gen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality.Cancer.2001; 92(9): 2309–2317.
20.
FowlerJ.E.Jr, TerrellF.. Survival in blacks and whites after treatment for localized prostate cancer.J Urol.1996; 156(1): 133–136.
21.
DuX.L., FangS., CokerA.L.. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort.Cancer.2006; 106(6): 1276–1285.
22.
PolednakA.P.. Prostate cancer treatment in black and white men: the need to consider both stage at diagnosis and socioeconomic status.J Natl Med Assoc.1998; 90(2): 101–104.
23.
ConliskE.A., LengerichE.J., Demark-WahnefriedW.. Prostate cancer: demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina.Urology.1999; 53(6): 1194–1199.
24.
TarmanG.J., KaneC.J., MoulJ.W.. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system.Urology.2000; 56(6): 1016–1020.
25.
BrawnP.N., JohnsonE.H., KuhlD.L.. Stage at presentation and survival of white and black patients with prostate carcinoma.Cancer.1993; 71(8): 2569–2573.
26.
OptenbergS.A., ThompsonI.M., FriedrichsP.. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system.JAMA.1995; 274(20): 1599–1605.
27.
DenbergT.D., BeatyB.L., KimF.J.. Marriage and ethnicity predict treatment in localized prostate carcinoma.Cancer.2005; 103(9): 1819–1825.
28.
PotoskyA.L., RileyG.F., LubitzJ.D.. Potential for cancer related health services research using a linked Medicare-tumor registry database.Med Care.1993; 31(8): 732–748.
29.
WarrenJ.L., KlabundeC.N., SchragD.. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.Med Care.2002; 40 (8 suppl): IV-3-18.
30.
MandelblattJ.S., KernerJ.F., HadleyJ.. Variations in breast carci-noma treatment in older medicare beneficiaries: is it black or white.Cancer.2002; 95(7): 1401–1414.
DuX.L., GoodwinJ.S.. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data.J Clin Oncol.2001; 19(5): 1455–1461.
33.
DuX.L., KeyC.R., DickieL.. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews.Med Care.2006; 44(2): 124–131.
34.
DuX., FreemanJ.L., GoodwinJ.S.. Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology and End Results.J Clin Epidemiol.1999; 52(5): 463–470.
35.
DuX.L., ChanW., GiordanoS.. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity.Cancer.2005; 104(5): 913–924.
36.
CharlsonM.E., PompeiP., AlesK.L.. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.J Chronic Dis.1987; 40(5): 373–383.
37.
KleinbaumD.G., KleinM., eds. Survival Analysis: A Self-Learning Text.New York, NY: Springer Science + Business Media, Inc; 1996.
38.
KlotzL.. Combined androgen blockade in prostate cancer: meta-analyses and associated issues.BJU Int.2001; 87(9): 806–813.
39.
WardE., JemalA., CokkinidesV.. Cancer disparities by race/ethnicity and socioeconomic status.CA Cancer J Clin.2004; 54(2): 78–93.
40.
HarlanL., BrawleyO., PommerenkeF.. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate.J Clin Oncol.1995; 13(1): 93–100.
41.
KlabundeC.N., PotoskyA.L., HarlanL.C.. Trends and black/white differences in treatment for nonmetastatic prostate cancer.Med Care.1998; 36(9): 1337–1348.
42.
ImperatoP.J., NennerR.P., WillT.O.. Radical prostatectomy: lower rates among African-American men.J Natl Med Assoc.1996; 88(9): 589–594.
43.
DeschC.E., PenberthyL., NewschafferC.J.. Factors that determine the treatment for local and regional prostate cancer.Med Care.1996; 34(2): 152–162.
44.
ShaversV.L., BrownM.L., PotoskyA.L.. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.J Gen Intern Med.2004; 19(2): 146–155.
45.
BurnsR.B., McCarthyE.P., FreundK.M.. Black women receive less mammography even with similar use of primary care.Ann Intern Med.1996; 125(3): 173–182.
46.
StegingaS.K., OcchipintiS., GardinerR.A.. Making decisions about treatment for localized prostate cancer.BJU Int.2002; 89(3): 255–260.
47.
Corbie-SmithG., ThomasS.B., St GeorgeD.M.. Distrust, race, and research.Arch Intern Med.2002; 162(21): 2458–2463.
48.
FowlerF.J.Jr, McNaughton CollinsM., AlbertsenP.C.. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer.JAMA.2000; 283(24): 3217–3222.
49.
Feldman-StewartD., BrundageM.D., HayterC.. What prostate cancer patients should know: variation in professionals’ opinions.Radiother Oncol.1998; 49(2): 111–123.
50.
BachP.B., CramerL.D., WarrenJ.L.. Racial differences in the treatment of early-stage lung cancer.N Engl J Med.1999; 341(16): 1198–1205.
51.
AkazaH.. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer.BJU Int.2004; 93(1): 42–46.
52.
KoffS.G., ConnellyR.R., BauerJ.J.. Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.Prostate Cancer Prostatic Dis.2002; 5(2): 152–158.
53.
WangY., SudilovskyD., ZhangB.. A human prostatic epithelial model of hormonal carcinogenesis.Cancer Res.2001; 61(16): 6064–6072.
54.
BoslandM.C.. The role of steroid hormones in prostate carcinogenesis.J Natl Cancer Inst Monogr.2000; (27): 39–66.
55.
WuA.H., WhittemoreA.S., KolonelL.N.. Lifestyle determinants of 5alpha-reductase metabolites in older African-American, white, and Asian-American men.Cancer Epidemiol Biomarkers Prev.2001; 10(5): 533–538.
56.
PlatzE.A., RimmE.B., WillettW.C.. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals.J Natl Cancer Inst.2000; 92(24): 2009–2017.
57.
KubrichtWSIII, WilliamsB.J., WhatleyT.. Serum testosterone levels in African-American and white men undergoing prostate biopsy.Urology.1999; 54(6): 1035–1038.
58.
GannP.H., HennekensC.H., MaJ.. Prospective study of sex hormone levels and risk of prostate cancer.J Natl Cancer Inst.1996; 88(16): 1118–1126.
59.
HeikkiläR., AhoK., HeliövaaraM.. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study.Cancer.1999; 86(2): 312–315.
60.
ThataiL.C., BanerjeeM., LaiZ.. Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer.Urolo-gy.2004; 64(4): 738–743.
61.
HornerR.D.. Racial variation in cancer care: a case study of prostate cancer.Cancer Treat Res.1998; 97: 99–114.
62.
TewariA., HorningerW., PelzerA.E.. Factors contributing to the racial differences in prostate cancer mortality.BJU Int.2005; 96(9): 1247–1252.
63.
PolednakA.P., FlanneryJ.T.. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut.Cancer.1992; 70(8): 2152–2158.
64.
RobbinsA.S., WhittemoreA.S., ThomD.H.. Differences in socioeconomic status and survival among white and black men with prostate cancer.Am J Epidemiol.2000; 151(4): 409–416.
65.
GodleyP.A., SchenckA.P., AmamooM.A.. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer.J Natl Cancer Inst.2003; 95(22): 1702–1710.
66.
GiovannucciE., RimmE.B., WolkA.. Calcium and fructose intake in relation to risk of prostate cancer.Cancer Res.1998; 58(3): 442–447.
67.
KientaK.J., DemersR., HoffM.. Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987.Urology.1995; 45(1): 93–101; discussion 101-102.
68.
RoachMIII, LuJ., PilepichM.V.. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.J Urol.2003; 169(1): 245–250.
69.
GeronimusA.T., BoundJ.. Use of census-based aggregate variables to proxy for socioeconomic group: evidence from national samples.Am J Epidemiol.1998; 148(5): 475–486.
70.
HolmesL.Jr, ChanW., JiangZ.. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.Prostate Cancer Prostatic Dis.2007; 10(4): 388–395. Epub 2007 May 8.
